Fingers crossed as Bydureon resubmitted in the US
This article was originally published in Scrip
Executive Summary
As expected, Amylin Pharmaceuticals, Lilly and Alkermes have submitted their reply to a complete response letter issued last year by the US FDA regarding Bydureon (exenatide extended-release for injectable suspension) for type 2 diabetes.